Search

Background and Objectives: Platelet concentrates suspended in a platelet additive solution (PAS‐PC) are associated with a reduction in allergic response and are suitable for preparing pathogen‐inactivated PC. We aimed to develop an efficient platform for the dual preparation of PAS‐PC and platelet‐poor plasma. Materials and Methods: PAS‐PC was prepared in six steps by using a hollow‐fibre system based on cross‐flow filtration: priming, loading PC, loading PAS, collection of filtered liquid (flow‐through) and collection of platelets by washing with PAS followed by washing with air. In this study, the efficacy of platelet and plasma protein recovery and characteristics of recovered PAS‐PC and flow‐through plasma were analysed in detail. Results: Recoveries of platelet in PAS‐PC and plasma protein in the flow‐through were 95.4% ± 3.7% and 61.6% ± 5.0%, respectively. The residual plasma protein in PAS‐PC was 34.1% ± 2.8%. Although the expression level of CD62P, a platelet activation marker, in recovered platelets was approximately 1.2‐fold of that in original platelets, swirling patterns were well retained, and aggregation in PAS‐PC was not visible. Agonist‐induced aggregabilities, platelet morphology and hypotonic shock recovery were conserved. The patterns of plasma protein and lipoprotein in the flow‐through were comparable with those in the original PCs. The multimeric pattern analysis of VWF remained unaltered. Conclusion: We propose a highly efficient preparation system that enables the simultaneous production of PAS‐PC and platelet‐poor plasma. It also achieves a high recovery of functionally well‐retained platelets with very low activation. [ABSTRACT FROM AUTHOR]

Background and objectives: Although HLA‐eliminated platelets can facilitate transfusions to patients possessing HLA antibodies, no such products are currently available commercially perhaps because the platelet collection rate is not yet economically viable. We have improved this process' efficiency by employing a hollow‐fibre system at the last step of the production process after an acid and a reaction buffer have been washed out conventionally by centrifugation. Materials and methods: HLA‐eliminated platelets were prepared via four distinct steps: chilled on ice, treated with an acid solution, diluted and finally washed using the hollow‐fibre system. The efficiency of this platelet recovery process was determined. The resulting products' platelet characteristics, including a capacity for HLA expression, were evaluated in vitro and compared in detail to their corresponding originals. Results: The average efficiency of platelet recovery was 91%. Although the expression levels of CD62P, a molecular marker for platelet activation, were approximately threefold higher on new platelets than on the original platelets, their HLA expression levels were lower. The phagocytosis assay, with monoclonal antibodies and cognate HLA antibody‐containing sera, suggested that HLA‐ABC molecules on the cell surface were sufficiently removed. The platelet functions, including the agonist‐induced aggregability and adherence/aggregability of the collagen‐coated plates under certain conditions, were conserved and not significantly different from the original ones. Conclusion: We propose a novel preparation system for producing HLA‐eliminated platelets without centrifugation, which ensures a highly efficient, and therefore, much more economical method of platelet recovery that also retains their key functionality. [ABSTRACT FROM AUTHOR]

Background and Objectives Materials and Methods Results Conclusion Quantifying the contribution of individual coagulation factors to haemostasis may aid our understanding of the haemostatic function in patients with rare coagulation deficiencies (RCDs) and the exploration of suitable treatments.Reconstituted blood prepared from specific coagulation factor‐deficient plasma (factor [F]II; prothrombin, FV, FVII, FVIII, FIX, FX, FXI or FXII) and red blood cell/platelet products were used to simulate the whole blood of patients with RCD. We prepared in vitro treatment models for patients with prothrombin deficiency using coagulation factor agents and fresh frozen plasma. Haemostatic function was measured using a microchip flow chamber system at 600 s−1.The haemostatic function was low, especially in blood samples reconstituted with prothrombin‐ and FX‐deficient plasma. In a plasma transfusion model of prothrombin deficiency, haemostatic function recovered after 10% replacement with normal plasma and reached a plateau at ≧60% replacement. A treatment model of prothrombin deficiency with prothrombin complex concentrates revealed dose‐dependent therapeutic effects in the range of 0–50 IU/kg.Microchip flow chamber system‐based quantification of haemostatic function using reconstituted blood could predict haemostasis and therapeutic effects of treatments in patients with prothrombin deficiency. [ABSTRACT FROM AUTHOR]